Molecular diagnostics and molecular tumor board in uro-oncology: Precision medicine using the example of metastatic castration-resistant prostate cancer

被引：0
作者：
Kornienko K. [1 ,2 ]
Tahbaz R. [1 ]
Plage H. [1 ]
Schlomm T. [1 ]
机构：
[1] Klinik für Urologie, Charité – Universitätsmedizin Berlin, Charitéplatz 1, Berlin
[2] Deutsches Krebsforschungszentrum, Heidelberg
来源：
best practice onkologie | 2022年 / 17卷 / 5期
关键词：
Interdisciplinary tumor board; Mutation; Next generation sequencing; Poly(ADP-ribose) polymerase inhibitors; Precision oncology;
D O I：
10.1007/s11654-022-00390-8
中图分类号：
学科分类号：
摘要：
Novel approaches to molecular tumor profiling evaluate DNA, RNA and protein alterations to create a detailed molecular map that enables precise and personalized treatment decisions. As the field of molecular profiling is constantly evolving, the training and networking of doctors is of decisive importance. Through the establishment of precision medicine with precision oncological consultations supported by interdisciplinary molecular tumor boards, many patients with difficult to treat tumor diseases can be advised and treated. Many pathophysiological relationships in progressive tumors can be elucidated resulting in new therapeutic options for the profiled patients; however, understanding the complex mutational profiles remains a very demanding task that requires a suitably trained and committed team that should be in close contact with the scientific advancements in precision oncology. © 2022, The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
引用
收藏
页码：238 / 249
页数：11
相关论文
共 35 条
  • [1] Dancey J.E., Bedard P.L., Onetto N., Hudson T.J., The genetic basis for cancer treatment decisions, Cell, 148, pp. 409-420, (2012)
  • [2] Gambardella V., Lombardi P., Carbonell-Asins J.A., Tarazona N., Cejalvo J.M., Gonzalez-Barrallo I., Et al., Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study, Br J Cancer, 125, pp. 1261-1269, (2021)
  • [3] Ku S.-Y., Gleave M.E., Beltran H., Towards precision oncology in advanced prostate cancer, Nat Rev Urol, 16, pp. 645-654, (2019)
  • [4] Malone E.R., Oliva M., Sabatini P.J.B., Stockley T.L., Siu L.L., Molecular profiling for precision cancer therapies, Genome Med, 12, (2020)
  • [5] Uddin M., Wang Y., Woodbury-Smith M., Artificial intelligence for precision medicine in neurodevelopmental disorders, Npj Digit Med, 2, (2019)
  • [6] El-Deiry W.S., Goldberg R.M., Lenz H.-J., Shields A.F., Gibney G.T., Tan A.R., Et al., The current state of molecular testing in the treatment of patients with solid tumors, 2019, CA Cancer J Clin, 69, pp. 305-343, (2019)
  • [7] Shen S.Y., Singhania R., Fehringer G., Chakravarthy A., Roehrl M.H.A., Chadwick D., Et al., Sensitive tumour detection and classification using plasma cell-free DNA methylomes, Nature, 563, pp. 579-583, (2018)
  • [8] Normanno N., Rachiglio A.M., Roma C., Fenizia F., Esposito C., Pasquale R., Et al., Molecular diagnostics and personalized medicine in oncology: challenges and opportunities, J Cell Biochem, 114, pp. 514-524, (2013)
  • [9] S3-Leitlinie Prostatakarzinom Version 6.0 – Mai 2021 AWMF-Registernummer: 043/022OL, (2021)
  • [10] Finkle J.D., Boulos H., Driessen T.M., Lo C., Blidner R.A., Hafez A., Et al., Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA, Npj Precis Oncol, 5, (2021)
1234